Korean J Gastroenterol.  2014 Oct;64(4):250-252. 10.4166/kjg.2014.64.4.250.

Can Non-invasive Fibrosis Assessment Predict Sustained Virological Response to Telaprevir with Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients?

• Kim MN
• Kim JH
• Kim SU

• KMID: 1979212
• DOI: http://doi.org/10.4166/kjg.2014.64.4.250

Abstract

No abstract available.

MeSH Terms

Fibrosis*
Hepatitis C, Chronic*
Humans
Interferons*
Ribavirin*
Interferons
Ribavirin

Reference

References

1. Ogawa E, Furusyo N, Shimizu M, et al. Noninvasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C. Antivir Ther. 2014. doi: 10.3851/IMP2805. [Epub ahead of print].

2. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002; 36(5 Suppl 1):S35–S46.

3. Wedemeyer H, Jensen DM, Godofsky E, Mani N, Pawlotsky JM, Miller V. Definitions/Nomenclature Working Group∗ of the HCV DrAG (HCV Drug Development Advisory Group), under the aus-pices of the Forum for Collaborative HIV Research. Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents. Hepatology. 2012; 56:2398–2403.

4. Zeuzem S, Andreone P, Pol S, et al. REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011; 364:2417–2428.

5. Cammà C, Petta S, Enea M, et al. WEF Study Group. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology. 2012; 56:850–860.

6. Bacon BR, Gordon SC, Lawitz E, et al. HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364:1207–1217.

7. Furusyo N, Ogawa E, Nakamuta M, et al. Kyushu University Liver Disease Study (KULDS) Group. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol. 2013; 59:205–212.

8. Serfaty L, Forns X, Goeser T, et al. Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1. Gut. 2012; 61:1473–1480.

9. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004; 127(5 Suppl 1):S27–S34.

10. Oka H, Kurioka N, Kim K, et al. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology. 1990; 12(4 Pt 1):680–687.

11. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012; 142:1293–1302.e4.

12. Kim JH, Kim MN, Han KH, Kim SU. Clinical application of transient elastography in patients with chronic viral hepatitis receiving antiviral treatment. Liver Int. 2014. doi: 10.1111/liv.12628. [Epub ahead of print].

13. Park MS, Han KH, Kim SU. Noninvasive prediction of development of hepatocellular carcinoma using transient elastography in patients with chronic liver disease. Expert Rev Gastroenterol Hepatol. 2014; 8:501–511.

14. Kang W, Kim SU, Ahn SH. Noninvasive prediction of forthcoming cirrhosis-related complications. World J Gastroenterol. 2014; 20:2613–2623.

15. Ogawa E, Furusyo N, Nakamuta M, et al. Kyushu University Liver Disease Study (KULDS) Group. Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study. Aliment Pharmacol Ther. 2013; 38:1076–1085.